Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Magrolimab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Gilead Sciences
Deal Size : $4,900.0 million
Deal Type : Acquisition
Gilead to Acquire Forty Seven for $4.9 Billion
Details : Gilead gains Forty Seven’s investigational immuno-oncology therapy in multiple clinical studies, supporting its strategic focus in oncology as well as innovative pipeline.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : $4,900.0 million
March 02, 2020
Lead Product(s) : Magrolimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Gilead Sciences
Deal Size : $4,900.0 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?